Sarah Boyce, President and CEO at Avidity Biosciences, Inc. (RNA), sold 84,000 shares at $20.13 ($1.7M) on 2024-03-01, disclosed to the SEC on 2024-03-05.
Scheduled sale ($1.7M) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| RNA | SELL | 2025-09-05 | $2.5M | — | Filing → |
| RNA | SELL | 2025-08-29 | $1.2M | — | Filing → |
| RNA | SELL | 2025-03-21 | $2.0M | — | Filing → |